Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 399

1.

Tailored antithrombotic therapy for acute coronary syndromes.

Fitchett D.

Expert Rev Cardiovasc Ther. 2008 Aug;6(7):935-44. doi: 10.1586/14779072.6.7.935. Review.

PMID:
18666844
2.

The medical management of acute coronary syndromes and potential roles for new antithrombotic agents.

Pollack CV Jr, Goldberg AD.

J Emerg Med. 2008 May;34(4):417-28. doi: 10.1016/j.jemermed.2007.08.058. Review.

PMID:
18226874
3.
4.

Avoiding and managing bleeding complications in patients with non-ST-segment elevation acute coronary syndromes.

Potsis TZ, Katsouras C, Goudevenos JA.

Angiology. 2009 Apr-May;60(2):148-58. doi: 10.1177/0003319708317339. Review.

PMID:
18508853
5.

Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.

Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S; OASIS 5 and 6 Investigators..

Circulation. 2008 Nov 11;118(20):2038-46. doi: 10.1161/CIRCULATIONAHA.108.789479. Erratum in: Circulation. 2008 Dec 16;118(25):e842.

6.

Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.

Chew DP, Huang Z, Pieper KS, White H, Mahaffey KW, Ferguson JJ, Califf RM, Aylward PG.

Am Heart J. 2008 Feb;155(2):239-44. doi: 10.1016/j.ahj.2007.10.002.

PMID:
18215592
7.

Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome.

Dobesh PP, Phillips KW, Haines ST.

Am J Health Syst Pharm. 2008 Aug 1;65(15 Suppl 7):S22-8. doi: 10.2146/ajhp080242.

PMID:
18653821
8.

Major bleeding: management and risk reduction in acute coronary syndromes.

Cavender MA, Rao SV, Ohman EM.

Expert Opin Pharmacother. 2008 Aug;9(11):1869-83. doi: 10.1517/14656566.9.11.1869 . Review.

PMID:
18627326
9.

Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.

Heer T, Juenger C, Gitt AK, Bauer T, Towae F, Zahn R, Senges J, Zeymer U; Acute Coronary Syndromes (ACOS) Registry Investigators..

J Thromb Thrombolysis. 2009 Oct;28(3):325-32. doi: 10.1007/s11239-008-0294-y.

PMID:
19101783
10.

Antiplatelet therapy: anti-ischemic benefits versus bleeding risk.

Gibson CM.

J Interv Cardiol. 2008 Dec;21 Suppl 1:S3-9. doi: 10.1111/j.1540-8183.2008.00407.x. Review.

PMID:
19090934
11.

Antithrombotic agents for acute coronary syndromes.

Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2008 Apr;6(2):130-41. Review.

PMID:
18473778
12.

Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.

Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB, Smith SC Jr, Peterson ED, Becker RC.

Am Heart J. 2008 Feb;155(2):361-8. doi: 10.1016/j.ahj.2007.09.003.

PMID:
18215609
13.

Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician.

Gharacholou SM, Lopes RD, Washam JB, Newby LK, James SK, Alexander JH.

J Thromb Thrombolysis. 2010 May;29(4):516-28. doi: 10.1007/s11239-009-0437-9. Review.

PMID:
20091089
14.

Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction.

Manoukian SV.

Am J Cardiol. 2009 Sep 7;104(5 Suppl):9C-15C. doi: 10.1016/j.amjcard.2009.06.020. Review.

PMID:
19695355
15.

Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.

Fitchett D, Goodman SG, Gupta M, Langer A.

Can J Cardiol. 2002 Nov;18(11):1179-90. Review.

PMID:
12464982
16.

Which heparin and how much?

Ruchin PE, Labinaz M.

Curr Cardiol Rep. 2008 Jul;10(4):312-8.

PMID:
18611366
17.

Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.

Karthikeyan G, Mehta SR, Eikelboom JW.

Expert Rev Cardiovasc Ther. 2009 Mar;7(3):241-9. doi: 10.1586/14779072.7.3.241.

PMID:
19296760
18.

Incidence, outcomes, and management of bleeding in non-ST-elevation acute coronary syndromes.

Gutierrez A, Rao SV.

Cleve Clin J Med. 2010 Jun;77(6):369-79. doi: 10.3949/ccjm.77a.09142.

19.

Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.

Motivala AA, Tamhane U, Saab F, Li J, Rogers EK, Froehlich J, Moscucci M, Eagle KA, Gurm HS.

Am J Cardiol. 2007 Nov 1;100(9):1359-63.

PMID:
17950790
20.

The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality.

Sobieraj-Teague M, Gallus AS, Eikelboom JW.

Curr Opin Cardiol. 2008 Jul;23(4):327-34. doi: 10.1097/HCO.0b013e3283021c5b. Review.

PMID:
18520716
Items per page

Supplemental Content

Support Center